Antibodies News and Research

RSS

Prior SARS-CoV-2 infection enhances Johnson and Johnson Ad26.COV2.S vaccine immunogenicity

A new study reports that the Johnson and Johnson vaccine against COVID-19 shows enhanced efficacy when administered to individuals with pre-existing antibodies.

30 Jul 2021

Scientists suspect Lambda SARS-CoV-2 variant most dangerous

A new study published on the bioRxiv* preprint server used molecular phylogenetic analysis to study the evolutionary trait of the Lambda variant.

30 Jul 2021

Phase 1/2 trial results for Nanocovax, protein subunit SARS-CoV-2 vaccine from Vietnam

Nanocovax is a protein subunit vaccine that contains the full-length spike stabilized by the addition of two prolines

29 Jul 2021

Streptococcus pneumoniae modulates host immunity to SARS-CoV-2

Scientists from the UK and US have recently investigated immunological consequences of secondary Streptococcus pneumoniae (S. pneumoniae) infection in coronavirus disease 2019 (COVID-19) patients.

29 Jul 2021

Study reveals cellular basis of antigen-specific response to Pfizer-BioNTech’s COVID-19 vaccine

Researchers in the United States have provided important insights into the antigen-specific cellular response and evolving humoral (antibody) response to messenger RNA- (mRNA) based vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

29 Jul 2021

Spike-containing virus-like particles induce robust sterilizing immunity against SARS-CoV-2 in macaques

A team of international scientists has recently developed virus-like particles (VLPs) by coating liposomes with the synthetic spike glycoprotein of SARS-CoV-2.

28 Jul 2021

Mini-antibodies efficiently block SARS-CoV-2 virus

Göttingen researchers have developed mini-antibodies that efficiently block the coronavirus SARS-CoV-2 and its dangerous new variants.

28 Jul 2021

Unraveling the mysterious mutations that make delta the most transmissible covid virus yet

Upon first inspection, the mutations in the highly contagious delta covid variant don't look that worrisome.

28 Jul 2021

Atlas Antibodies acquires evitria

Atlas Antibodies has agreed to acquire evitria, a world leader in transient recombinant antibody expression in CHO cells. This transformative acquisition brings together a leading provider of highly validated research antibodies and a front-runner in the field of custom recombinant antibody expression.

From Atlas Antibodies 28 Jul 2021

SARS-CoV-2 variants of concern employ different strategies of antibody escape

A recent study in the field of fluid analysis reveals a diverse set of strategies utilized by alpha and beta variants of the severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) in order to evade antibodies generated during an earlier infection with this virus. The paper is currently available on the bioRxiv* preprint server while it undergoes a peer-review process.

28 Jul 2021

How do people with post acute sequelae of COVID-19 react to SARS-CoV-2 vaccines?

A new study focuses on the impact of vaccines on the changes in the symptoms in the PASC group.

27 Jul 2021

Immunity to SARS-CoV-2 in renal transplant and dialysis patients using Pfizer/BioNTech and Moderna vaccines

A study analyzes the immune responses of medical personnel, as well as immunocompromised DP and immunosuppressed KTR patients.

27 Jul 2021

SARS-CoV-2 spike-specific antibodies induced in breast milk by COVID-19 vaccines

An interesting new paper examines how these vaccines can help young patient populations to withstand the virus.

27 Jul 2021

Study suggests mRNA SARS-CoV-2 vaccines remain effective against variants

A study reports that many VOCs are associated with impaired reduction in their susceptibility to neutralization by COVID-19 vaccines.

27 Jul 2021

T cells are not critical for recovery of primates from acute COVID-19 infections, study reveals

New research conducted in monkeys reveals that T cells are not critical for the recovery of primates from acute COVID-19 infections.

27 Jul 2021

Impaired immune response to SARS-CoV-2 mRNA vaccination in immunocompromised patients

A new study describes how immunocompromised vaccine recipients may not always respond as expected to the COVID-19 vaccine.

27 Jul 2021

PerkinElmer to Acquire Antibody and Reagent Leader BioLegend

PerkinElmer, Inc. today announced it has entered into an agreement to acquire BioLegend, a leading, global provider of life science antibodies and reagents.

From Revvity 27 Jul 2021

Monoclonal antibody CT-P59 demonstrates potent antiviral efficacy against SARS-CoV-2 delta variant

A Korean study has recently demonstrated antiviral potency of monoclonal antibody CT-P59 against the delta variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The experiments conducted in animals infected with the delta variant have shown that CT-P59 is able to reduce symptom intensity and viral replication in the respiratory tract. The study is currently available on the bioRxiv* preprint server.

27 Jul 2021

A novel interferon-γ release assay for detection of SARS-CoV-2 specific T-cell response

A new study evaluates a commercially available IFN‐γ release assay (IGRA) to determine T-cell responses targeted against SARS-CoV-2.

26 Jul 2021

Researchers develop new exosome formulation to deliver VEGF antibodies for synergistic therapy

Researchers from the Institute of Process Engineering of the Chinese Academy of Sciences, Beijing Chaoyang Hospital and the University of Queensland have developed a new formulation based on regulatory T-cell exosomes (rEXS) to deliver vascular endothelial growth factor (VEGF) antibodies for choroidal neovascularization therapy.

26 Jul 2021

Antibodies News and Research

Prior SARS-CoV-2 infection enhances Johnson and Johnson Ad26.COV2.S vaccine immunogenicity

Scientists suspect Lambda SARS-CoV-2 variant most dangerous

Phase 1/2 trial results for Nanocovax, protein subunit SARS-CoV-2 vaccine from Vietnam

Streptococcus pneumoniae modulates host immunity to SARS-CoV-2

Study reveals cellular basis of antigen-specific response to Pfizer-BioNTech’s COVID-19 vaccine

Spike-containing virus-like particles induce robust sterilizing immunity against SARS-CoV-2 in macaques

Mini-antibodies efficiently block SARS-CoV-2 virus

Unraveling the mysterious mutations that make delta the most transmissible covid virus yet

Atlas Antibodies acquires evitria

SARS-CoV-2 variants of concern employ different strategies of antibody escape

How do people with post acute sequelae of COVID-19 react to SARS-CoV-2 vaccines?

Immunity to SARS-CoV-2 in renal transplant and dialysis patients using Pfizer/BioNTech and Moderna vaccines

SARS-CoV-2 spike-specific antibodies induced in breast milk by COVID-19 vaccines

Study suggests mRNA SARS-CoV-2 vaccines remain effective against variants

T cells are not critical for recovery of primates from acute COVID-19 infections, study reveals

Impaired immune response to SARS-CoV-2 mRNA vaccination in immunocompromised patients

PerkinElmer to Acquire Antibody and Reagent Leader BioLegend

Monoclonal antibody CT-P59 demonstrates potent antiviral efficacy against SARS-CoV-2 delta variant

A novel interferon-γ release assay for detection of SARS-CoV-2 specific T-cell response

Researchers develop new exosome formulation to deliver VEGF antibodies for synergistic therapy

How to make hybridoma-based antibody discovery more efficient eBook

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest Life Science News